Stay updated on Ibrutinib+Bendamustine/Rituximab in Mantle Cell Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Ibrutinib+Bendamustine/Rituximab in Mantle Cell Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ibrutinib+Bendamustine/Rituximab in Mantle Cell Lymphoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page now displays the study record for the phase II trial of DCVax-L and nivolumab for recurrent glioblastoma, including its withdrawn status and detailed study information, rather than a 403 error page.
    Difference
    77%
    Check dated 2026-11-08T12:58:08.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The site footer revision label changed from v3.7.2 to v3.8.0; the study page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T13:22:19.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    An NIH sitewide notice appears above the 403 error page, linking to transition updates and stating that federal agencies are using “Super Intelligence” in place of “Artificial Intelligence.”
    Difference
    1%
    Check dated 2026-10-25T13:12:28.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.1 to v3.7.2 on the 403 Forbidden page.
    Difference
    0.2%
    Check dated 2026-10-18T14:46:47.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now shows revision v3.7.1 instead of v3.7.0; the page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T14:59:49.000Z thumbnail image
  7. Check
    57 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, indicating the study record is temporarily inaccessible.
    Difference
    23%
    Check dated 2026-09-20T22:26:18.000Z thumbnail image

Stay in the know with updates to Ibrutinib+Bendamustine/Rituximab in Mantle Cell Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ibrutinib+Bendamustine/Rituximab in Mantle Cell Lymphoma Clinical Trial page.